CCS1477 clinical trials
Also written CCS1477 and Inobrodib.
How each study uses CCS1477 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CCS1477 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
CellCentric Ltd. (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test CCS1477.
- Mar 2027Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesPhase 1/2 · CellCentric Ltd.
Studies
Open first, then newest update. How each study uses CCS1477 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaRecruitingPhase 2CellCentric Ltd.NCT07096778Written as Inobrodib
- Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple MyelomaRecruitingPhase 3CellCentric Ltd.NCT07772024Written as InoPd
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesRecruitingPhase 1/2CellCentric Ltd.NCT04068597Written as CCS1477
- Study to Evaluate CCS1477 in Advanced TumoursCompletedPhase 1/2CellCentric Ltd.NCT03568656Written as CCS1477
Codes
What other systems call CCS1477 · ClinicalTrials.gg INT001804
- MeSH (NLM) C000721532CCS1477Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) BW5QA5GEW7INOBRODIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000721532 | CCS1477 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | BW5QA5GEW7 | INOBRODIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.